No new signals for lecanemab emerged in ALZ-NET ...

Investigational deramiocel is back under FDA review again ...

Well, I read the upgrade today by Wells Fargo, and it talked about a bunch of revenue streams. including Alzheimer’s, and it ...

While Big Pharmas embarked on a frenzy of acquisitions over recent weeks, Roche’s CEO has explained to Fierce Biotech why the ...

Biogen (NASDAQ:BIIB) picked up a strong endorsement from Wall Street on Wednesday, as UBS analyst Michael Yee upgraded the ...

In this article, we will look at Jim Cramer’s stock calls on Mad Money recently. The host of Mad Money said Monday that the ...

Biogen Inc. (NASDAQ: BIIB) has recently been upgraded to a “Buy” rating by UBS analyst Michael Yee, with a new price target set at $225, signaling strong upside potential from the current trading ...

Futures are trading higher as we hit the midweek point. All major indices finished lower on Tuesday as the deadline for the ...

The investment bank upgraded the pharmaceutical name to buy from neutral. It also hiked its price target on shares to $225 ...

Biogen Inc. has consolidated full global rights to felzartamab through an $850 million deal with TJ Biopharma Co. Ltd. April ...

Agilent's Technologies' Joydeep Ganguly brought a surgeon's precision to LogiPharma Vienna and a radical vision for the ...

AES, InterDigital, Infleqtion, Netskope, and Biogen. Got a confidential news tip? We want to hear from you. Sign up for free ...